Merck Receives Fast-Track Designation for Tepotinib in Non-Small Cell Lung Cancer in Japan
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Japanese Ministry of Health, Labour and Welfare Grants SAKIGAKE designation for tepotinib, Merck's investigational highly selective c-Met receptor tyrosine kinase inhibitor - First regulatory designation for tepotinib - SAKIGAKE ...